

## Purixan<sup>®</sup> (mercaptopurine) – First-time generic

- On February 27, 2025, [Hikma launched](#) an [AB-rated](#) generic version of Nova Laboratories' [Purixan \(mercaptopurine\)](#) oral suspension.
  - The FDA granted Competitive Generic Therapy (CGT) designation with 180 days of exclusivity to Hikma for generic Purixan.
- Purixan is approved for the treatment of patients with acute lymphoblastic leukemia as part of a combination chemotherapy maintenance regimen.
- Mercaptopurine is also available as a generic [tablet](#) carrying the same indication as Purixan.
- According to IQVIA<sup>™</sup>, Purixan had U.S. sales of approximately \$14 million in the 12 months ending December 2024.